Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

RIGL

+ Watchlist+ Portfolio

Rigel Pharmaceuticals, Inc.

Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$42.92
52-Week Range
$24.95 – $52.61
Market Cap
$800.84M
P/E (TTM)
2.65
EPS (TTM)
16.07
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.79
PEG Ratio
—
Return on Equity
109.18%
Return on Assets
12.35%
Gross Margin
70.69%
Operating Margin
26.28%
Profit Margin
106.59%
Current Ratio
2.39
Debt/Equity
0.02
Total Debt
$7.79M
Free Cash Flow
$-8.59M
Revenue Growth
16.50%
Earnings Growth
-55.50%
Enterprise Value
$709.33M

Market Snapshot

About

Rigel Pharmaceuticals is a biotechnology company focused on discovering and developing small molecule drugs for hematologic disorders, cancer, and rare immune diseases. The company has developed approved therapies and maintains a pipeline of clinical and preclinical candidates. Rigel uses its expertise in intracellular signaling pathways to identify novel therapeutic targets.